FDA Approves Kalydeco (VX-770)
Kalydeco has been approved for children 6 years and older with at least one G551D mutation. This is the first drug that acts directly on the defective CFTR protein that causes CF. Click here for more information. Putting Parents in Charge of Meals: Behavioral Strategies to Help Parents and Kids Meet CF Dietary Recommendations
Dr. Lori Stark's presentation on behavioral interventions that can help children with CF achieve optimal nutritional goals is available online. Dr. Stark is the Director of Behavioral Medicine and Clinical Psychology at University of Cincinnati College of Medicine, Click here to view the presentation. Subscribe to eCystic Fibrosis Review
Our monthly continuing education newsletter reviewing the latest CF literature will be delivered to your email every month, Click here to subscribe. Family Education Day Presentations Are Online
The presentations from our Annual Family Education Day held on November 19th can be viewed by clicking here.
Introduction and 2011 Highlights, Dr. Peter Mogayzel
Research Advances, Dr. Michael Boyle
Environmental and Genetic Influences on CF Lung Disease, Dr. J. Michael Collaco
Click here to watch. It Is that Time of Year Again
Get your flu shot to stay healthy this winter. influenza vaccinations are available at your primary care physician's office or in CF Clinic. Everyone over 6 months old and not allergic to eggs should get vaccinated even if they do not have CF. Vertex Pharmaceuticals, Inc., announced it has submitted an application to the U.S. FDA for a potential new CF therapy, VX-770 — under its new proposed trade name KALYDECO. Are You Following Us on Facebook and Twitter?
The Johns Hopkins CF Center has launched pages on both Facebook and Twitter. Check us out!
New CFRD Handbook from the CF Foundation is Available
The latest edition of this excellent resource on CF-Related Diabetes is now available. Click here for a copy. Now Enrolling for the MPEX 209 Research Study
(MP-376, an inhaled levofloxacin solution vs. inhaled tobramycin)
We are now enrolling CF patients, ages 12 and up with chronic Pseudomonas aeruginosa lung infection, who have received multiple previous courses of an inhaled tobramycin. For more information click here. Guide about Admission to the Children's Center is Available
The Family Advisory Board has created a guide to help children and families admitted to the Children's Center. This book is filled with information about what happens during a hospital admission. Click here for a copy. Did You Know that Our Previous Educational Events Are Online?
Dr. Steven Rowe's lecture on "Advances in CF Therapeutics" is now available online. Watch the video now.
The talks from our 2010 Family Education Day, can be viewed online by clicking here. All the talks can be viewed including: Dr. Preston Campbell, Executive Vice President for Medical Affairs of the CF Foundation. View a presentation by Dr. Kerem, a world known leader in CF research, who has been at the forefront of the development of PTC124.. | 
